GlassScriptPhysician profile
Robert Earl Gardner
NPI 1649365917
$171,226.74
in general payments reported to CMS, 2019-2025
67 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $41K · 2021: $31K · 2022: $52K · 2023: $7,022 · 2024: $6,859 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $11K · Travel and Lodging: $858 · Consulting Fee: $675 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,931.25 |
| Food and Beverage | $11,083.62 |
| Travel and Lodging | $857.67 |
| Consulting Fee | $675.00 |
| Education | $299.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71,674.89 | 2020-2025 | |
| Amgen INC. | $36,071.30 | 2019-2025 | Uplizna, Aimovig |
| Allergan, INC. | $29,622.03 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $11,933.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,772.02 | 2022 | |
| Janssen Pharmaceuticals, INC | $1,744.23 | 2021-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $1,722.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,642.28 | 2019-2025 | |
| Biogen, INC. | $1,019.25 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $965.48 | 2020-2025 | |
| Greenwich Biosciences, INC. | $840.46 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $709.30 | 2019-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $681.79 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $643.96 | 2019-2025 | Ultomiris |
| Harmony Biosciences LLC | $634.64 | 2022-2025 | Wakix |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $530.26 | 2019-2025 | Kisunla, Amyvid, Zepbound |
| Ucb, INC. | $495.59 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Genentech USA, INC. | $459.46 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $455.73 | 2019-2025 | |
| Sk Life Science, INC. | $436.95 | 2021-2025 | Xcopri |
| Pfizer INC. | $391.99 | 2019-2025 | |
| Csl Behring | $357.56 | 2019-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $338.79 | 2019-2021 | |
| Celgene Corporation | $331.55 | 2021-2025 | Zeposia |
| Tg Therapeutics, INC. | $329.94 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $300.49 | 2019-2025 | Crexont, Rytary |
| Avadel Cns Pharmaceuticals, LLC | $281.95 | 2024-2025 | Lumryz |
| Astrazeneca Pharmaceuticals LP | $272.45 | 2022-2025 | Andexxa, Wainua |
| Ipsen Biopharmaceuticals, INC | $257.56 | 2019-2025 | Dysport |
| Neurocrine Biosciences, INC. | $237.59 | 2022-2025 | Ongentys, Ingrezza |
| Argenx US, INC. | $234.22 | 2024-2025 | Vyvgart Hytrulo |
| E.R. Squibb & Sons, L.L.C. | $225.46 | 2024-2025 | Zeposia |
| Lundbeck LLC | $217.91 | 2019-2025 | Vyepti |
| Janssen Biotech, INC. | $206.50 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $187.61 | 2023-2025 | Nuedexta, Rexulti |
| Neurelis, INC. | $185.88 | 2020-2025 | Valtoco |
| Emd Serono, INC. | $164.33 | 2020-2024 | |
| Acorda Therapeutics, INC | $128.85 | 2021-2023 | Inbrija, Ampyra |
| Acadia Pharmaceuticals INC | $122.78 | 2022-2025 | Nuplazid |
| Medtronic, INC. | $119.08 | 2021-2025 | Percept PC Brainsense, Activa PC |
| Bausch Health US, LLC | $115.11 | 2019 | |
| Impel Pharmaceuticals INC. | $111.71 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $110.58 | 2023-2025 | Sunosi, Symbravo |
| Octapharma USA, INC. | $74.46 | 2022-2024 | Panzyga |
| Adamas Pharmaceuticals, INC. | $73.26 | 2020-2021 | |
| Grifols USA, LLC | $71.10 | 2023-2025 | Gamunex-C |
| Akcea Therapeutics, INC. | $68.86 | 2019-2020 | |
| Ge Healthcare | $67.14 | 2021-2025 | |
| Mdd US Operations, LLC | $66.99 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $62.10 | 2023-2024 | Fycompa |
| Corium, LLC | $60.40 | 2023 | Adlarity |
| Avion Pharmaceuticals | $47.29 | 2022-2023 | Dhivy |
| Mallinckrodt Hospital Products INC. | $40.11 | 2020-2025 | Acthar |
| Vanda Pharmaceuticals INC. | $33.41 | 2025 | Ponvory |
| Upsher-Smith Laboratories LLC | $32.60 | 2019 | |
| Xeris Pharmaceuticals, INC. | $30.40 | 2022-2023 | Keveyis |
| Promius Pharma LLC | $28.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $26.76 | 2019-2022 | |
| Cala Health, INC. | $22.70 | 2023 | Cala Trio |
| Abbott Laboratories | $22.57 | 2025 | Infinity |
| Hospira, INC. | $18.27 | 2025 | |
| Sumitomo Pharma America, INC. | $18.18 | 2024 | Aptiom |
| Tanabe Pharma America, INC. | $16.83 | 2023 | |
| Apria Healthcare LLC | $16.36 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.14 | 2023 | |
| Merz Pharmaceuticals, LLC | $14.38 | 2025 | Ampyra, Inbrija, Xeomin |
| Itamar Medical INC | $12.91 | 2025 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.